Central Idea

India has achieved a significant milestone in the field of cancer treatment with the approval of NexCAR19, its first indigenous CAR-T Cell Therapy, by the Central Drugs Standard Control Organisation (CDSCO).
Developed by ImmunoACT, an incubated company of IIT Bombay, NexCAR19 is set to transform cancer treatment in India and make it more affordable.

What is CAR-T Cell Therapy?

Revolutionary Approach: CAR-T cell therapy involves modifying T-cells, a type of white blood cell, into potent cancer-fighting cells.
Targeting Cancer: These genetically enhanced cells are reintroduced into the patient’s body, where they identify and eliminate cancer cells, particularly effective against blood cancers like leukemia and lymphomas.
Game-Changer: Unlike chemotherapy or immunotherapy, CAR-T therapy offers the potential for a cure and lifelong benefits, making it a transformative treatment option.

NexCAR19 is designed to target cancer cells carrying the CD19 protein, a marker on cancer cells, enhancing precision in treatment.
India joins a select group of nations with its own CAR-T and gene therapy platform, reducing dependence on imports.
Initially approved for patients aged 15 and above with B-cell lymphomas who did not respond to standard treatments, leading to relapse or recurrence.

Approximately 70% of patients respond to NexCAR19 treatment, with some achieving complete remission.
Lab and animal studies indicate lower drug-related toxicities, including reduced neurotoxicity and Cytokine Release Syndrome (CRS).
Trials for paediatric patients are underway at Tata Memorial Hospital, ensuring broader applicability.

ImmunoACT is in the process of securing licenses and partnering with hospitals, including Tata Memorial, Nanavati, Fortis, and Jaslok, across multiple cities.
CAR-T therapy is expected to be available in a matter of weeks to a few months, pending final government approvals.
Initially priced at Rs 30-40 lakh, ImmunoACT aims to eventually reduce the cost to Rs 10-20 lakh, making the therapy more accessible.
Approval by regulatory agencies like CDSCO should lead to insurance coverage, but the extent may vary, and discussions with insurers and the government are ongoing.